What changed: Male breast cancer
Every dated change on the records linked to Male breast cancer, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Trial result1Guideline2Milestone6This record1
September 2026 · 1
2021 · 2
2020 · 3
- 2020GuidelineMale breast cancerGuideline ASCO 2020 male breast cancer guideline: Adjuvant endocrine, ER-positive
Tamoxifen for five to ten years; aromatase inhibitor only with GnRH agonist suppression if tamoxifen is contraindicated.
- 2020GuidelineMale breast cancerGuideline NCCN Guidelines: Breast Cancer (special considerations for men); ASCO guideline on management of male breast cancer 2020: Early stage
Mastectomy (or breast conservation where feasible) with sentinel node biopsy; adjuvant radiotherapy by the same criteria as women; chemotherapy and HER2-directed therapy as indicated. (NCCN Category 2A)
- 2020MilestoneMale breast cancerASCO guideline and FDA guidance
First ASCO guideline on male breast cancer; FDA guidance on including men in breast cancer drug development.